Novartis
NVS
1,202 hedge funds and large institutions have $14.9B invested in Novartis in 2023 Q2 according to their latest regulatory filings, with 100 funds opening new positions, 340 increasing their positions, 476 reducing their positions, and 69 closing their positions.
131% more call options, than puts
Call options by funds: $677M | Put options by funds: $292M
45% more first-time investments, than exits
New positions opened: 100 | Existing positions closed: 69
2% more funds holding
Funds holding: 1,181 → 1,202 (+21)
1.02% less ownership
Funds ownership: 8.1% → 7.08% (-1%)
7% less funds holding in top 10
Funds holding in top 10: 14 → 13 (-1)
29% less repeat investments, than reductions
Existing positions increased: 340 | Existing positions reduced: 476
81% less capital inflows, than outflows
Capital inflows: $561M | Capital outflows: $2.88B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
+$67.3M |
| 2 |
Morgan Stanley
New York
|
+$65.1M |
| 3 |
Clark Capital Management Group
Philadelphia,
Pennsylvania
|
+$39.4M |
| 4 |
Magnetar Financial
Evanston,
Illinois
|
+$33M |
| 5 |
D.E. Shaw & Co
New York
|
+$26.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$710M |
| 2 |
Dodge & Cox
San Francisco,
California
|
-$391M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$261M |
| 4 |
Goldman Sachs
New York
|
-$175M |
| 5 |
Primecap Management
Pasadena,
California
|
-$142M |
NVS Hedge Fund Activity: Q2 2023 in Review
1,202 of the 6,390 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q2 2023, worth a combined $14.9B — down 1.6% from $15.2B a quarter earlier.
Buyers outnumbered sellers: 100 funds opened new NVS positions and 69 closed out — a net gain of 31 holders — while 340 added to existing stakes and 476 trimmed.
The largest buyer was Grantham, Mayo, Van Otterloo & Co (GMO), adding an estimated $67.3M. The largest seller was Envestnet Asset Management, cutting an estimated $710M.
- 1,202 institutional investors held Novartis (NVS) as of Q2 2023, up from 1,181 in Q1 2023.
- Funds reported $14.9B of Novartis stock for Q2 2023, down 1.6% quarter-over-quarter.
- 100 funds opened new Novartis positions in Q2 2023 and 69 closed out, a net change of +31 holders.
- The largest Novartis buyer in Q2 2023 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $67.3M added.
- The largest Novartis seller in Q2 2023 was Envestnet Asset Management, an estimated $710M sold.
Based on aggregated 13F filings for Q2 2023.